Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus low-energy diet for early cardiac effects in adults with obesity and cardiovascular disease
ACTRN12626001332314Phase 4Not yet recruiting
- Sponsor
- Monash University
- Start
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Monash University. Primary endpoint: Myocardial energetics (PCr/ATP). Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ACTRN12626001332314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001332314.